This systematic review evaluates the safety and effectiveness of Nicotinamide adenine dinucleotide (NAD+) and its precursors as human supplements across various clinical conditions.
Researchers analyzed ten randomized controlled trials, encompassing 489 participants with conditions such as chronic fatigue syndrome, Parkinson’s, and Alzheimer’s disease, or healthy individuals. The review concludes that NAD+ supplementation, particularly NADH and nicotinamide riboside (NR), is generally well-tolerated with a low incidence of mild side effects, such as muscle pain and headaches.
While findings suggest potential benefits like improved quality of life, reduced anxiety, and enhanced cognitive function in specific conditions, the authors emphasize the need for further high-quality research with standardized dosages and outcomes to solidify these conclusions.
